Liverpool Street, London Bridge, High St Kensington, and Mayfair
Rubenstein JH, Inadomi JM, Scheiman J, Schoenfeld P, Appelman H, Zhang M, Metko V, Kao JY (2014) Association between Helicobacter pylori and Barrett's esophagus, erosive esophagitis, and gastroesophageal reflux symptoms
The FDA's recent guidance on obesity drug development has emphasized the importance of patient-reported outcomes and quality of life measures in addition to traditional weight loss endpoints
Of their many claims in court documents, plaintiffs say Eli Lilly: Overstated the efficacy of Cymbalta and downplayed and/or failed to state the true withdrawal side effects associated with Cymbalta Failed to properly warn patients about the risks and of the frequency, severity, and/or duration of Cymbalta withdrawal Benefitted from patients who started taking Cymbalta again (becoming physically dependent on the drug) to avoid terrible side effects Advertised the benefits of the drug, even those that were not proven Produced a defective drug The lawsuits also say Eli Lilly deceived the public by including in the drugs label that only 1% of users experienced withdrawal symptoms, when in reality studies show between 44% and 50% suffered from discontinuation problems
